Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

Inclusion Criteria: * Previously untreated, histological documented stage IIIB (not amenable for radical regional therapy) or stage IV squamous cell carcinoma of lung. At least one measurable lesion as defined by RECIST criteria. * At least 18 years of age. * ECOG PS 0\~1 * Patients have no previously malignant tumor history except cured cervical carcinoma in situ, basal cell carcinoma or superficial bladder cancer. Patients are also eligible if they have received a chemotherapy regimen as neoadjuvant or adjuvant chemotherapy and the disease recurred over 12 months since the finishing of neoadjuvant or adjuvant chemotherapy. * neutrophil ≥ 1.5 x 109 /L, Hemoglobin \> 90 g/L, Platelet count \> 100x109/L. * Total bilirubin ≤ 1.5 x upper limit of normal. ALT and AST \< 2.5 x upper limit of normal without liver metastasis, ALT and AST \< 5 x upper limit of normal with liver metastasis. Serum creatinine \< 1.5 x upper limit of normal. * Urine pregnancy test is negative for woman. * Estimated life expectancy is at least 3 months. * Patient comply with the clinical trial protocal. * Informed consent must be signed. Exclusion Criteria: * Patients who are currently undergoing other anti-tumor therapy. * Patients who was enrolled in any other clinical trial within 4 weeks of study entry. * Any physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any study medication or render the subject at high risk from treatment. * Central nervous system (CNS) tumor or metastatic tumor. * Serious mental disorder. * Serious dysgnosia. * Other serious comorbidity. * Alcohol or drug dependence. * Previously allergic to drugs used in the study.